Title
Time to Recognize HIV Infection as a Major Cardiovascular Risk Factor

Permalink
https://escholarship.org/uc/item/305367cf

Journal
Circulation, 138(11)

ISSN
0009-7322

Authors
Hsue, Priscilla Y
Waters, David D

Publication Date
2018-09-11

DOI
10.1161/circulationaha.118.036211

Peer reviewed
EDITORIAL

Time to Recognize HIV Infection as a Major Cardiovascular Risk Factor

According to statistics from the World Health Organization, ≈36.7 million people are currently living with HIV, and 1.8 million become infected every year. Antiretroviral therapy has largely transformed HIV infection into a chronic disease. As a consequence, it is estimated that by the year 2030, 73% of HIV-infected individuals will be ≥50 years of age, and 78% of individuals living with HIV will have cardiovascular disease (CVD). Individuals infected with HIV have a significantly increased risk for a variety of cardiovascular complications, including acute myocardial infarction, heart failure with both reduced and preserved ejection fraction, sudden cardiac death, peripheral arterial disease, and stroke. In the United States, CVD has become a key contributor to mortality among individuals living with HIV.

The systematic review of longitudinal studies of CVD in HIV by Shah and colleagues in this issue of Circulation includes 80 studies with 793,635 individuals living with HIV and a follow-up of 3.5 million person-years. A random-effects meta-analysis was performed to derive a pooled rate and risk of CVD among people living with HIV and to estimate the burden of CVD and HIV at the national, regional, and global levels. The authors report that the relative risk of CVD in persons living with HIV is 2.16 (95% CI, 1.68–2.77) as compared with uninfected individuals. Over the past 26 years, the global population attributable fraction from CVD in the setting of HIV increased from 0.36% (95% CI, 0.21–0.56) to 0.92% (95% CI, 0.55–1.41), and disability-adjusted life-years increased from 0.74 (95% CI, 0.44–1.16) to 2.57 (95% CI, 1.53–3.92) million. Most of these increases took place in sub-Saharan Africa and the Asia Pacific regions.

The authors deserve high praise for the vast scope of their study and the large volume of work involved. Some of their findings confirm previous studies but on a broader scale (eg, the risk of incident CVD being 2-fold higher in HIV and similar to other high-risk groups such as patients with diabetes mellitus). Most of the limitations of the study are inherent in this type of research and are unavoidable. First, myocardial infarction and stroke are defined differently across the aggregated studies, and the majority of cases were not clinically adjudicated but were categorized using coding. This lack of standardization of myocardial infarction definition may be particularly problematic in HIV, where approximately half are type 2 (ie, demand related, such as in the setting of sepsis or illicit drug use).

Second, in a meta-analysis such as this without patient-level data, the contributions of traditional risk factors (eg, high levels of smoking and the metabolic syndrome) and HIV-specific risk factors (eg, HIV medication, degree of HIV control, level of inflammation) cannot be adjusted for or even ascertained. In addition, the cardiovascular risk of patients infected with HIV is likely distinctly different before

Key Words: Editorials • xxx • xxx

© 2018 American Heart Association, Inc.
https://www.ahajournals.org/journal/circ
and after the introduction of antiretroviral therapy. Although the authors report that the impact of HIV and CVD was highest among individuals in sub-Saharan Africa, this finding is based on only a small number of studies from this region; most of the data come from the United States and Europe. All of these issues likely contributed to the substantial heterogeneity for pooled risk ratios, as noted by the authors.

However, despite these limitations, the study by Shah et al demands our attention because of its global scope and sobering conclusions: a doubling of cardiovascular risk in people living with HIV, coupled with a tripling of the global burden of CVD in HIV. What are the implications of these findings?

Among the general population, the relative impact of traditional risk factors has been shifting over the past 2 to 3 decades. Hypercholesterolemia can now be well controlled with drug therapy in most patients, and control of hypertension has improved, at least in wealthier countries. The incidence and prevalence of type 2 diabetes mellitus has increased dramatically across most of the globe because of a higher prevalence of overweight and obesity, but outcomes in well-treated patients with established diabetes mellitus has improved. The impact of smoking on cardiovascular risk has diminished because smoking rates have decreased in many countries and many at-risk groups, whereas in other places, little progress has been made.

Although HIV accounts for a relatively small proportion of CVD compared with these major risk factors, the relative risk of a cardiovascular event in a person living with HIV is in the range of traditional risk factors. The Figure compares the relative risk and population attributable risk of HIV from the study of Shah et al and odds ratios and traditional risk factors from the INTERHEART study (XXXX). Because odds ratios can give inflated estimates of risk when the outcome is common, it is likely that the relative risks of traditional risk factors in INTERHEART are smaller and thus closer to that of HIV. Although the relative risk is unlikely to change much, the impact of HIV on CVD can only worsen as the HIV population ages. Has the time come to recognize HIV infection as a major cardiovascular risk factor, alongside diabetes mellitus, hypertension, hyperlipidemia, and smoking?

Such recognition might have salutary consequences. First, elevating HIV infection to the status of a major cardiovascular risk factor might stimulate research in this area. Treatment of CVD among individuals living with HIV relies on clinical trial data from non-HIV populations, although HIV-associated atherosclerosis has distinct features (such as more noncalcified plaques) and mechanisms, including chronic inflammation/immune activation and the impact of antiretroviral therapy. Clinical trial data specific to HIV would be helpful; however, it is not feasible in an era of limited resources to do outcome-driven clinical trials for all types of interventions and patient populations. As such, smaller proof-of-concept mechanistic studies that target HIV-specific factors will be critical to move the field forward. Precision medicine approaches, including omics methodologies, studies of healthcare disparities, digital monitoring, and implementation science aimed at cardiovascular risk in HIV, will also be invaluable.

It is important to note that elevating HIV to the level of the other major risk factors could improve awareness, and thus the prevention, detection, and treatment of CVD among individuals living with HIV, along with better control of their traditional risk factors. All of these things could theoretically reduce CVD and CVD mortality in HIV. Often neither the HIV specialist nor the cardiologist has the requisite knowledge to treat these individuals optimally, and awareness among all caregivers of the excess cardiovascular risk remains crucial. Traditional risk calculators underestimate cardiovascular risk in HIV, but recognition of HIV as a major risk factor would
reduce the need for risk calculation. The European Society of Cardiology guidelines recommend lipid-lowering therapy to reduce low-density lipoprotein cholesterol to <70 mg/dL in individuals infected with HIV.\textsuperscript{14}

In 2004, our group reported rapid carotid artery intima-media progression in HIV and concluded that this finding would presage a high rate of cardiovascular events.\textsuperscript{15} Fourteen years later, the study by Shah et al\textsuperscript{6} confirms this high rate of cardiovascular events on a global scale. The rate continues to increase even in the setting of treated and suppressed HIV disease. The key challenges for cardiologists and HIV clinicians continue to be unraveling the mechanisms underlying HIV-associated atherosclerosis, accurately predicting individuals at risk, and providing interventions to reduce this risk. The time to consider HIV as a cardiovascular risk factor is now.

**ARTICLE INFORMATION**

**Correspondence**
Priscilla Hsue, MD, Room S51 Cardiology, Zuckerberg San Francisco General Hospital, 1001 Potrero Avenue, San Francisco, CA 94110. Email priscilla.hsue@ucsf.edu

**Affiliation**
University of California San Francisco, Zuckerberg San Francisco General Hospital.

**Sources of Funding**
This work was funded in part by the National Institute of Allergy and Infectious Diseases (K24AI112393 to P.Y.H.).

**Disclosures**
Dr Hsue has received honoraria from Gilead and Merck outside of the submitted work. Dr Waters reports no conflicts of interest.

**REFERENCES**


AUTHOR QUERIES

Authors please note: Authors are responsible for any page charges as outlined in the acceptance letter or as indicated on the Instructions for Authors (http://circ.ahajournals.org/content/accepted-manuscripts). Unless you have selected open access for your article, or it is otherwise noted on the acceptance letter, page charges are as follows: $70 per black and white page (print articles only) or $35 per page (online-only articles only). For each color page (print only), please add $653/page. If there are any concerns regarding these charges, these should be addressed within 48 hours of receiving the s-proof. Author(s) will be invoiced for all color and page charges post publication. If you have selected open access for your article, please refer to details in the queries below.

AUTHOR PLEASE ANSWER ALL QUERIES

AQ1—Please turn to page 2 of your proof and review the author’s name and short title in the running head. Short titles must be 50 or fewer characters in length, including spaces and punctuation. If your original short title was longer than 50 characters, we may have shortened it. Please modify if necessary (but observe our length guidelines).

AQ2—Please provide subject codes for your article. See "https://eur01.safelinks.protection.outlook.com/?url=https%3A%2F%2Fdownload.lww.com%2Fwolterskluwer_vitalstream_com%2FPermaLink%2FCIRC%2FA%2FCIRC_2016_06_12_CODES_001234_SDC123.pdf&data=02%7C01%7C%7C222da9a4da604495d5d108d5dc47df27%7C84df9e7fe9f640af4b435aaaaaaaaaaa%7C1%7C0%7C636657124375510740&dataa=8oTDfjxlvOuqav9U5qwLJrrN28mbgsTi4PMUIV2cY%3D&reserved=0" _blank" to select appropriate codes

AQ3—For indexing purposes, confirm author names have been correctly identified as given names (blue), surnames (red), and suffixes (black). Color in the byline will not appear on the final published version.

AQ4—Key words may have been edited to match the US National Library of Medicine’s Medical Subject Headings (http://www.nlm.nih.gov/mesh/MBrowser.html). If they need modification, please refer to this site and limit the total number of key words to 7.

AQ5—If you have color in your proof, please indicate whether you approve the color charge by returning the color agreement with your corrections. The color agreement can be found at “http://links.lww.com/circ/A10” . The rate is $653 per 1 printed color page. If you prefer black and white figures, please indicate so on your proof corrections. If you have any questions, please contact "mailto:circulationjournal@lww.com"

AQ6—Spell out study name per journal style

AQ7—Please spell out study name

AQ8—Please confirm that all authors’ institutional affiliations (including city/state/country locations) are correct as shown.
AQ9—Please carefully review any Acknowledgments, Sources of Funding, and/or Disclosures listed at the end of the manuscript (before the References) and confirm that they are accurate and complete for all authors.
AQ10—Please provide doi# and exact PAP URL
AQ11—Folios for the article being discussed will be added in proofs.